A different bispecific, humanized IgG1 antibody that is beneath investigation is zenocutuzumab (MCLA-128), which acts by way of two impartial mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells via ADCC. MCLA-128 functions via a ‘dock and block’ system whereby a single arm of your antibody binds https://www.directivepublications.org/journal-of-clinical-breast-cancer/